Predict your next investment

Venture Capital
mavf.com

See what CB Insights has to offer

Investments

137

Portfolio Exits

29

Funds

4

About Mid-Atlantic Venture Funds

The Mid-Atlantic Venture Funds are four private venture capital partnerships (the first two were called NEPA Venture Funds) with approximately $200 million under management. Our primary investment interest is in purchasing the equity securities of new, young or growing businesses located in the Mid-Atlantic, although we can invest elsewhere, and have. MAVF seeks to invest in young high growth potential businesses of almost any type. Their preference is to invest as early as possible including the "angel"" stage."

Mid-Atlantic Venture Funds Headquarter Location

Ben Franklin Technology Center, Lehigh University 125 Goodman Drive

Bethlehem, Pennsylvania, 18015,

United States

(610) 865-6550

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Mid-Atlantic Venture Funds News

Viaken Systems Closes $13 Million in Second Round Financing Repeat investors include, Core Capital Partners and Mid-Atlantic Venture Funds.

Jan 6, 2017

Sterling Venture Partners Leads Round, Including Allianz, MacAndrews & Forbes And Returning Investors, Core Capital and Mid-Atlantic Venture Funds 25 Jun, 2001, 01:00 ET from Viaken Systems Inc. GAITHERSBURG, Md., June 25 /PRNewswire/ -- (BIO 2001, booth #1237) Viaken Systems Inc. (Viaken(TM)), the end-to-end bioinformatics solutions provider to the biopharmaceutical industry, today announced that it has secured second round equity funding totaling $13 million. The financing comes from lead investor Sterling Venture Partners, and new participating investors MacAndrews & Forbes, Allianz, Schoffstall Ventures, and e-media. "We are thrilled to welcome Sterling, MacAndrews & Forbes, and Allianz to our team, and to receive the continued support of Mid-Atlantic and Core Capital," stated Keith Elliston, chairman, president, and CEO of Viaken Systems. "Viaken has established its position as the total solution provider to the biotech and pharmaceutical industries, and is financially positioned to lead the way in bioinformatics solution deployment and support." "Viaken's end-to-end informatics solution model will have a significant impact on the future of drug discovery," said Michael Bronfein, managing general partner at Sterling Ventures. "The Viaken platform provides customers with accelerated access to state-of-the-art bioinformatics solutions, with greatly reduced implementation risk. Their experienced management team and key industry alliances and partnerships have positioned them to provide the biotech and pharmaceutical markets with top-level informatics solutions to meet the mission-critical needs of research and development departments." This second round of funding will help fund the company's expansion of its sales and marketing efforts and its professional services activities, and further invest in its developing data products business. The Viaken offering includes secure managed services, domain expert professional services, productized solutions for bioinformatics, integrated data products, and collaborative research. The Viaken end-to-end approach enables it to serve state-of-the-art bioinformatics solutions not only to top tier pharmaceutical companies, but also to the small and midsize biotechnology and pharmaceutical customer. The integrated solutions methodology ensures that the customer has a complete solution to fulfill their bioinformatics needs, allowing them to concentrate on their key competitive advantage -- their science. "This round of financing represents an important step in the growth of the company," said Tom Smith, Viaken director and general partner of Mid-Atlantic Venture Funds. "To raise funds in a challenging economic environment from a quality group of investors is validation of the company's strategy. Biotech and pharmaceutical companies are in need of solutions to help them stay competitive in the market. Viaken's total solutions strategy enables companies of all sizes to rapidly deploy quality bioinformatics solutions to speed the drug discovery process." "Viaken is a company with a very experienced and expert management team, and has built a strong basis for rapid growth," emphasized Mark Levine, managing director of Core Capital. "This round of financing from such a well- respected syndicate of investors is proof of the strong business strategy that Viaken has put in place. The Viaken solutions model is filling the void in the market for bioinformatics services, as a partner for life science companies." About Sterling Venture Partners Sterling Venture Partners is a venture capital fund investing in early- stage companies in the Mid-Atlantic and Midwest. Sterling's areas of focus are telecommunications, enterprise software, healthcare technology and education. With substantial investment and operating experience, the fund's principals provide critical resources to help entrepreneurs and their companies realize their full potential. Sterling Venture Partners has offices in Baltimore and Chicago and is affiliated with Sterling Capital, Ltd., a private equity firm founded in 1983. For more information on Sterling Venture Partners, visit http://www.sterlingcap.com . About Core Capital Partners Core Capital Partners, LP. is a $160 million fund headquartered in Washington, D.C., which provides both venture and growth capital to technology companies throughout the Mid-Atlantic region. For more information on Core, please visit the website: http://www.core-capital.com . About Mid-Atlantic Venture Funds For over 15 years, Mid-Atlantic Venture Funds has been a leading provider of early stage equity capital to emerging technology companies in the Mid- Atlantic region. Partners Fred Beste, Glen Bressner, Marc Benson and Tom Smith manage the firm's investment activities from offices in Bethlehem, PA and Reston, VA. About Viaken Viaken Systems is the end-to-end bioinformatics solutions provider, offering enabling solutions for biotechnology, pharmaceutical, and agricultural research and development. Viaken provides a range of bioinformatics solutions including hosting and managed services, strategic design and implementation services, integrated data products, collaborative research, and technical and scientific user support and training to its customers in the life sciences. The company has developed a secure optimized hosting platform called the Viaken Informatics Environment that provides its customers with access to scalable informatics platforms customizable to their specific needs, and a line of productized solutions -- the Viaken Discovery System series. For more information on Viaken, visit http://www.viaken.com . Viaken is a trademark of Viaken Systems Inc. All other trademarks mentioned in this document are the property of their respective owners. MAKE YOUR OPINION COUNT - Click Here http://tbutton.prnewswire.com/prn/11690X41134114 SOURCE Viaken Systems Inc. GAITHERSBURG, Md., June 25 /PRNewswire/ -- (BIO 2001, booth #1237) Viaken Systems Inc. (Viaken(TM)), the end-to-end bioinformatics solutions provider to the biopharmaceutical industry, today announced that it has secured second round equity funding totaling $13 million. The financing comes from lead investor Sterling Venture Partners, and new participating investors MacAndrews & Forbes, Allianz, Schoffstall Ventures, and e-media. "We are thrilled to welcome Sterling, MacAndrews & Forbes, and Allianz to our team, and to receive the continued support of Mid-Atlantic and Core Capital," stated Keith Elliston, chairman, president, and CEO of Viaken Systems. "Viaken has established its position as the total solution provider to the biotech and pharmaceutical industries, and is financially positioned to lead the way in bioinformatics solution deployment and support." "Viaken's end-to-end informatics solution model will have a significant impact on the future of drug discovery," said Michael Bronfein, managing general partner at Sterling Ventures. "The Viaken platform provides customers with accelerated access to state-of-the-art bioinformatics solutions, with greatly reduced implementation risk. Their experienced management team and key industry alliances and partnerships have positioned them to provide the biotech and pharmaceutical markets with top-level informatics solutions to meet the mission-critical needs of research and development departments." This second round of funding will help fund the company's expansion of its sales and marketing efforts and its professional services activities, and further invest in its developing data products business. The Viaken offering includes secure managed services, domain expert professional services, productized solutions for bioinformatics, integrated data products, and collaborative research. The Viaken end-to-end approach enables it to serve state-of-the-art bioinformatics solutions not only to top tier pharmaceutical companies, but also to the small and midsize biotechnology and pharmaceutical customer. The integrated solutions methodology ensures that the customer has a complete solution to fulfill their bioinformatics needs, allowing them to concentrate on their key competitive advantage -- their science. "This round of financing represents an important step in the growth of the company," said Tom Smith, Viaken director and general partner of Mid-Atlantic Venture Funds. "To raise funds in a challenging economic environment from a quality group of investors is validation of the company's strategy. Biotech and pharmaceutical companies are in need of solutions to help them stay competitive in the market. Viaken's total solutions strategy enables companies of all sizes to rapidly deploy quality bioinformatics solutions to speed the drug discovery process." "Viaken is a company with a very experienced and expert management team, and has built a strong basis for rapid growth," emphasized Mark Levine, managing director of Core Capital. "This round of financing from such a well- respected syndicate of investors is proof of the strong business strategy that Viaken has put in place. The Viaken solutions model is filling the void in the market for bioinformatics services, as a partner for life science companies." About Sterling Venture Partners Sterling Venture Partners is a venture capital fund investing in early- stage companies in the Mid-Atlantic and Midwest. Sterling's areas of focus are telecommunications, enterprise software, healthcare technology and education. With substantial investment and operating experience, the fund's principals provide critical resources to help entrepreneurs and their companies realize their full potential. Sterling Venture Partners has offices in Baltimore and Chicago and is affiliated with Sterling Capital, Ltd., a private equity firm founded in 1983. For more information on Sterling Venture Partners, visit http://www.sterlingcap.com . About Core Capital Partners Core Capital Partners, LP. is a $160 million fund headquartered in Washington, D.C., which provides both venture and growth capital to technology companies throughout the Mid-Atlantic region. For more information on Core, please visit the website: http://www.core-capital.com . About Mid-Atlantic Venture Funds For over 15 years, Mid-Atlantic Venture Funds has been a leading provider of early stage equity capital to emerging technology companies in the Mid- Atlantic region. Partners Fred Beste, Glen Bressner, Marc Benson and Tom Smith manage the firm's investment activities from offices in Bethlehem, PA and Reston, VA. About Viaken Viaken Systems is the end-to-end bioinformatics solutions provider, offering enabling solutions for biotechnology, pharmaceutical, and agricultural research and development. Viaken provides a range of bioinformatics solutions including hosting and managed services, strategic design and implementation services, integrated data products, collaborative research, and technical and scientific user support and training to its customers in the life sciences. The company has developed a secure optimized hosting platform called the Viaken Informatics Environment that provides its customers with access to scalable informatics platforms customizable to their specific needs, and a line of productized solutions -- the Viaken Discovery System series. For more information on Viaken, visit http://www.viaken.com . Viaken is a trademark of Viaken Systems Inc. All other trademarks mentioned in this document are the property of their respective owners. MAKE YOUR OPINION COUNT - Click Here http://tbutton.prnewswire.com/prn/11690X41134114 SOURCE Viaken Systems Inc.

Mid-Atlantic Venture Funds Investments

137 Investments

Mid-Atlantic Venture Funds has made 137 investments. Their latest investment was in BeneFix as part of their Series A on August 8, 2020.

CBI Logo

Mid-Atlantic Venture Funds Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

8/21/2020

Series A

BeneFix

$3.85M

No

1

12/10/2019

Seed - V

BeneFix

$4.22M

Yes

1

6/29/2007

Convertible Note

CorePROFIT

$0.45M

No

1

1/15/2007

Series B

Subscribe to see more

$99M

Subscribe to see more

0

10/9/2006

Series D

Subscribe to see more

$99M

Subscribe to see more

0

Date

8/21/2020

12/10/2019

6/29/2007

1/15/2007

10/9/2006

Round

Series A

Seed - V

Convertible Note

Series B

Series D

Company

BeneFix

BeneFix

CorePROFIT

Subscribe to see more

Subscribe to see more

Amount

$3.85M

$4.22M

$0.45M

$99M

$99M

New?

No

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

1

1

0

0

Mid-Atlantic Venture Funds Portfolio Exits

29 Portfolio Exits

Mid-Atlantic Venture Funds has 29 portfolio exits. Their latest portfolio exit was Hurwitz & Associates on October 13, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

10/13/2021

Acquired

$99M

1

11/7/2016

Acquired

$99M

3

9/30/2011

Acquired

$99M

10/22/2008

Acquired

Subscribe to see more

$99M

Subscribe to see more

0

9/8/2008

Acquired

Subscribe to see more

$99M

Subscribe to see more

0

Date

10/13/2021

11/7/2016

9/30/2011

10/22/2008

9/8/2008

Exit

Acquired

Acquired

Acquired

Acquired

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

1

3

0

0

Mid-Atlantic Venture Funds Acquisitions

1 Acquisition

Mid-Atlantic Venture Funds acquired 1 company. Their latest acquisition was CEMA Technologies on September 27, 1998.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

9/27/1998

Series B

$99M

$1.35M

Acquired

Date

9/27/1998

Investment Stage

Series B

Companies

Valuation

$99M

Total Funding

$1.35M

Note

Acquired

Sources

Mid-Atlantic Venture Funds Fund History

4 Fund Histories

Mid-Atlantic Venture Funds has 4 funds, including Mid-Atlantic Venture Fund IV LP.

Closing Date

Fund

Fund Type

Status

Amount

Sources

12/31/2000

Mid-Atlantic Venture Fund IV LP

Multi-Stage Venture Capital

Closed

$112M

1

6/1/1998

Mid-Atlantic Venture Fund III LP

Subscribe to see more

Subscribe to see more

$99M

10

1/1/1992

NEPA Venture Fund II LP

Subscribe to see more

Subscribe to see more

$99M

10

12/31/1986

NEPA Venture Fund I LP

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

12/31/2000

6/1/1998

1/1/1992

12/31/1986

Fund

Mid-Atlantic Venture Fund IV LP

Mid-Atlantic Venture Fund III LP

NEPA Venture Fund II LP

NEPA Venture Fund I LP

Fund Type

Multi-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Closed

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$112M

$99M

$99M

$99M

Sources

1

10

10

10

Mid-Atlantic Venture Funds Team

10 Team Members

Mid-Atlantic Venture Funds has 10 team members, including current Founder, Managing Partner, Glen R. Bressner.

Name

Work History

Title

Status

Glen R. Bressner

Founder, Managing Partner

Current

Marc F. Benson

General Partner

Current

Frederick J. Beste

Chief Executive Officer

Former

Michael T Long

Chief Financial Officer

Former

Myer M Alperin

General Partner

Former

Name

Glen R. Bressner

Marc F. Benson

Frederick J. Beste

Michael T Long

Myer M Alperin

Work History

Title

Founder, Managing Partner

General Partner

Chief Executive Officer

Chief Financial Officer

General Partner

Status

Current

Current

Former

Former

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.